Rongping Dai, MD, Youxin Chen, MD; You-xin Chen | Department of Ophthalmology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences
Competition Sponsor: Chinese Academy of Medical Sciences
Award year: 2021
There are about 10 million patients with pathologic myopia in China. Pathologic myopia has now become one of the major fundus diseases which may cause blindness. The operation of posterior scleral reinforcement or compression is a feasible method to treat macula diesease by preventing scleral expansion for patients with pathologic myopia. Allogeneic sclera reinforcement is now mostly applicated, but accompanied by many problems, such as many surgical complications, the limited source of materials and the involvement of ethical issues.
The patented rebounding posterior scleral reinforcement device is made of elastic resin and will be implanted into patients with pathologic myopia. The rebound device is expected to be easy to operate with highly effectiveness. The device will solve the problem of limited sources of autologous scleral materials.
The objective of this research is to demonstrate its effectiveness and safety of the device, laying the foundation for the following clinical trials.